The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses

Abstract

Thirty-eight female patients (age range: 31-79 years) with breast masses underwent technetium-99m methoxyisobutylisonitrile (99mTc-MIBI) breast scintigraphy in order to assess the value of this technique in the detection of breast carcinomas and in their differentiation from benign breast masses. The results showed that 27 of the 32 cases of breast carcinoma were detected by 99mTc-MIBI breast scintigraphy. In contrast, none of the six benign lesions could be detected by this method. The diagnostic sensitivity, specificity and accuracy were 84%, 100% and 87%, respectively, in the differentiation of malignant and benign breast masses. In conclusion, we consider 99mTc-MIBI breast scintigraphy is useful in distinguishing malignancies from benign breast masses.

Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial

“…The accumulation of 99m Tc-MIBI in the tumour is dependent on the quantity of mitochondria in the tumour cell, on the electric membrane potential and on the expression of the multidrug resistance (MDR) gene [42][43][44][45][46]. Recent studies using 99m Tc-MIBI for breast cancer detection have shown high sensitivity and specificity for palpable cancers [22][23][24][25][26][27][28][29][30][31][32]. For non-palpable breast lesions, diagnostic accuracy has been less favorable [25,27,29,30].…”

“…Disease with a high inflammatory component might yield false-positive results, most likely due to increased local perfusion. Areas with increased mitochondrial activity and density, such as juvenile adenomas and hyperproliferative disease, can also cause false-positive MIBI uptake [22,25,27,29]. However, patients with atypical hyperproliferative disease have a higher relative risk for breast cancer [52].…”

“…A number of studies have demonstrated high diagnostic accuracy of 99m Tc-MIBI for the detection of breast cancer [22][23][24][25][26][27][28][29][30][31][32]. Therefore, this multicentre trial was set up to confirm the value of scintimammography using 99m Tc-MIBI.…”

Molecular Imaging in TB: From the Bench to the Clinic

“…However, as previously stated, many benign and malignant etiologies can also demonstrate 99m Tc-MIBI uptake (Aktolun et al, 1991;Caner et al, 1992;Kao et al, 1994;A. Yang et al, 2007), which significantly decreases the value of this radiotracer in the differential diagnosis of pulmonary TB from other lung pathologies.…”

“…99m Tc-MIBI is a widely used myocardial perfusion agent, which can accumulate in tumours and inflammatory lesions (Aktolun et al, 1991;Caner et al, 1992;Kao et al, 1994;A. Yang et al, 2007).…”